Cargando…
Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series
BACKGROUND: Rituximab (RTX) is a standard therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the most frequently used dose may lead to severe adverse effects (SAEs). We explored the efficacy and safety of low-dose RTX in Chinese patients with AAV. METHODS: A...
Autores principales: | Liu, Lin, Lu, Haitao, Zou, Guming, Wang, Haifeng, Li, Jing, Yang, Yue, Zhang, Jian, Wang, Xueling, Li, Wenge, Zhuo, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906883/ https://www.ncbi.nlm.nih.gov/pubmed/36755215 http://dx.doi.org/10.1186/s12882-023-03075-8 |
Ejemplares similares
-
Spotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectives
por: Moog, Philipp, et al.
Publicado: (2015) -
Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022) -
Comparison of Two Rituximab Induction Regimens for Antineutrophil Cytoplasm Antibody–Associated Vasculitis: Systematic Review and Meta‐Analysis
por: Bénard, Valérie, et al.
Publicado: (2021) -
Evaluation of Rituximab for Induction and Maintenance Therapy in Patients 75 Years and Older With Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
por: Thietart, Sara, et al.
Publicado: (2022) -
Analysis of treatment outcomes in patients with antineutrophil cytoplasmic antibody-associated vasculitis on rituximab therapy
por: Yoneva, Tsvetelina, et al.
Publicado: (2022)